Business
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients1-3 Fabhalta is first and only approved complement inhibitor for adults with IgAN and has potential to delay disease progression4,5 Fabhalta received accelerated approval for
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":287,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jVHT.jc1r.9_PBg7JQVa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":287,"height":55}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1","length":196,"tagName":"p"}]},{"val":[{"type":"text","content":"eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients1-3 ","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Fabhalta is first and only approved complement inhibitor for adults with IgAN and has potential to delay disease progression4,5 ","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Fabhalta received accelerated approval for reduction of proteinuria in adults with IgAN in US in 2024; data support 2026 submission for traditional FDA approval4,5 ","length":163,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":619,"olType":false},{"type":"text","content":"Basel, October 16, 2025 – Novartis today announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta® (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta, an oral alternative complement pathway inhibitor, demonstrated statistically significant, clinically meaningful superiority compared to placebo in slowing IgAN progression measured by annualized total slope of estimated glomerular filtration rate (eGFR) decline over two years1.","length":479,"tagName":"p"},{"type":"text","content":"“Progressive diseases such as IgAN present an urgent need for interventions that can ultimately improve kidney health. Many people with IgAN commonly experience fear and anxiety of disease progression,” said Ruchira Glaser, Development Unit Head, Cardiovascular, Renal & Metabolic, Novartis. “We are excited about t...